[
    [
        {
            "time": "",
            "original_text": "本土Biotech后浪生猛，跨国MNC群狼环伺，传统药企如何破局创新转型？从Me-too到BIC，License-in已成首选？",
            "features": {
                "keywords": [
                    "本土Biotech",
                    "跨国MNC",
                    "传统药企",
                    "创新转型",
                    "Me-too",
                    "BIC",
                    "License-in"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "制药行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "本土Biotech后浪生猛，跨国MNC群狼环伺，传统药企如何破局创新转型？从Me-too到BIC，License-in已成首选？",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]